You are here
Vivendi Activist Investor Should Agitate to Eliminate Sky High Corporate Costs
Media Mentions | March 26, 2015 | Forbes
Professor Ava Seave bylines article discussing the excessive cost for media conglomerate, Vivendi to maintain a corporate operation managing completely disparate divisions.
The Investors Behind the Kraft-Heinz Merger
Media Mentions | March 25, 2015 | Marketplace Radio
Professor Donna Hitscherich weighs in on the Kraft-Heinz merger, noting that the devil is always in the details.
Hedge Fund Everest Capital Falls off a Swiss Cliff
Media Mentions | March 16, 2015 | CNBC
Professor Michael Weinberg comments on Everest Capital’s currency bet on the Swiss franc.
Ackman Hasn’t Backed down an Inch: Savoldelli
Media Mentions | March 13, 2015 | Bloomberg TV
Professor Fabio Savoldelli discusses the government’s probe into Bill Ackman’s firm for possible market manipulation of Herbalife.
Buyouts Snapshot: Vista Equity’s Robert Smith Unapologetic for Big Step-Up in Fund Size
Media Mentions | March 09, 2015 | peHUB
Keynote speaker, Robert F. Smith ’94, founder, chairman and CEO, Vista Equity Partners, remarks at the School’s 21st Annual Private Equity & Venture Capital Conference is highlighted.
Barclays Charge, BOE Dismissal, Stress Tests: Compliance
Media Mentions | March 04, 2015 | Bloomberg News
Research co-authored by Professor Paul Glasserman, finds stress tests, a key tool for setting bank capital levels, have become more predictable and therefore arguably less informative.
Nasdaq 5k: Survivor CEOs
Media Mentions | February 25, 2015 | Nightly Business Report
Professor William Klepper discusses how four CEOs have lasted more than a decade at the helm of companies such as Amazon and Starbucks.
The Management Mistakes That Attract Activist Investors
Media Mentions | January 06, 2015 | Forbes
Professor Ava Seave identifies five triggers that are considered to be catalysts for shareholder activism.
Bill Ackman Won Both Ways on Allergan Deal: George
Media Mentions | November 17, 2014 | Bloomberg TV
Professor Fabio Savoldelli comments on Actavis’ acquisition of Allergan.
- 1 of 8
- Older items